Neil Woodford was once one of the brightest stars in Britain’s investment firmament. Then he came crashing down to earth. John Stepek explains what went wrong.
The Woodford Patient Capital investment trust continues to remain in limbo. Don’t bet on a turnaround anytime soon.
The price of the Woodford Patient Capital investment trust has fallen so far that you may think it looks like a bargain buy. Think again, says John Stepek.
From Neil Woodford to St James’s Place, skewed financial incentives mean investors’ well-being may not necessarily be a wealth manager’s top priority.
Worried that your manager might “do a Woodford”? Here’s what to look out for when investing in active funds.
John Stepek examines Neil Woodford’s progress in fixing his Equity Income Fund, and asks if it’s worth buying the Patient Capital Trust instead – while running his eye over an alternative trust for your portfolio.
The consequences from the Neil Woodford debacle aren’t limited to his fund’s investors. He and his ilk could pose a systemic risk to the financial system, says Merryn Somerset Webb.
Star fund manager Neil Woodford got into trouble with small, illiquid assets. Scott Longley explains what investors should look out for when sizing up smaller companies.
In the wake of Neil Woodford’s woes, fund manager H2O Asset Management has now been hit by concerns over illiquid assets in its portfolio. So how big a deal is this? And what can investors do about it? John Stepek explains.
Peter Hargreaves created a FTSE 100 company from scratch without borrowing or acquisition – and without scandal – at least until the Woodford one blew up in its face.
Neil Woodford had humble origins, but built an enthusiastic following among retail investors by promising to make them rich. Now, they’d just like their money back.